Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1994-6-23
|
pubmed:abstractText |
It is now widely accepted that insulin-like growth factor-I (IGF-I) has a local regulatory role in bone remodeling. IGF-I has also been demonstrated to regulate proliferation of bone-derived endothelial cells. Such studies suggest a role of IGF-I in skeletal angiogenesis. Using BBE cells, a bovine bone endothelial cell line, we characterized the kinetics and chemical properties of IGF-I receptors and examined the effect of IGF-I on bone endothelium migration. Two classes of binding sites with high affinity for IGF-I were detected by binding experiments on bone endothelial cells. Both competition analyses and cross-linking studies revealed the presence of type I IGF receptor in bone endothelial cells. Moreover, these cells produced and released authentic IGF-I into the medium, as evidenced by radioimmunoassay analyses of gel-filtered conditioned media. Both IGF-I binding capacity and release decreased either with increases in cell number or after treatment with 17 beta-estradiol (17 beta E2) and parathyroid hormone (PTH). Both hormones also inhibited chemotactic responses of bone endothelial cells to IGF-I. Taken together, these results strongly suggest that IGF-I, a growth factor that promotes the proliferation of various bone cell types, also induces growth and chemotactic responses in bone endothelium acting through the type I IGF receptor. This may be part of a generalized response of bone cells to IGF-I that facilitates cell migration.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor I,
http://linkedlifedata.com/resource/pubmed/chemical/Parathyroid Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, IGF Type 1,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0884-0431
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
329-37
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:8191926-Analysis of Variance,
pubmed-meshheading:8191926-Animals,
pubmed-meshheading:8191926-Binding, Competitive,
pubmed-meshheading:8191926-Bone and Bones,
pubmed-meshheading:8191926-Cattle,
pubmed-meshheading:8191926-Cell Division,
pubmed-meshheading:8191926-Cell Line,
pubmed-meshheading:8191926-Chemotaxis,
pubmed-meshheading:8191926-Chromatography, Gel,
pubmed-meshheading:8191926-Endothelium,
pubmed-meshheading:8191926-Estradiol,
pubmed-meshheading:8191926-Insulin-Like Growth Factor I,
pubmed-meshheading:8191926-Parathyroid Hormone,
pubmed-meshheading:8191926-Radioimmunoassay,
pubmed-meshheading:8191926-Receptor, IGF Type 1,
pubmed-meshheading:8191926-Recombinant Proteins
|
pubmed:year |
1994
|
pubmed:articleTitle |
Characterization, regulation, and function of specific cell membrane receptors for insulin-like growth factor I on bone endothelial cells.
|
pubmed:affiliation |
Department of Clinical Physiopathology, University of Florence, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|